{"id":"cpt-11-irinotecan","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"60-80","effect":"Nausea/vomiting"},{"rate":"15-20","effect":"Alopecia"},{"rate":"30-40","effect":"Anemia"},{"rate":"25-35","effect":"Abdominal pain"},{"rate":"40-50","effect":"Asthenia/fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan is a semisynthetic derivative of camptothecin that inhibits topoisomerase I, an enzyme essential for DNA replication and transcription. By stabilizing the topoisomerase I-DNA complex, the drug prevents religation of DNA strands, causing double-strand breaks during S-phase and triggering apoptosis in rapidly dividing cancer cells. The active metabolite SN-38 is responsible for most of the drug's cytotoxic activity.","oneSentence":"CPT-11 (irinotecan) is a topoisomerase I inhibitor that prevents DNA unwinding and repair, leading to DNA damage and cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:57.196Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (first-line and second-line)"},{"name":"Small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT00045201","phase":"PHASE1","title":"Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06-13","conditions":"Adult Solid Neoplasm","enrollment":60},{"nctId":"NCT02595931","phase":"PHASE1","title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT05694715","phase":"PHASE1","title":"Combination Therapy in Cancers With Mutations in DNA Repair Genes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-05-23","conditions":"Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT07466316","phase":"PHASE3","title":"A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Rhabdomyosarcoma","enrollment":342},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT03365882","phase":"PHASE2","title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2017-11-27","conditions":"Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma","enrollment":240},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07056777","phase":"PHASE1, PHASE2","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Zhejiang Doer Biologics Co., Ltd.","startDate":"2025-03-25","conditions":"Gastrointestinal Cancer","enrollment":186},{"nctId":"NCT03290937","phase":"PHASE1","title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":34},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT02192359","phase":"PHASE1","title":"Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-03-07","conditions":"Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma","enrollment":18},{"nctId":"NCT01864109","phase":"PHASE2","title":"Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Newly Diagnosed Ewing Sarcoma","enrollment":83},{"nctId":"NCT04205968","phase":"PHASE2","title":"Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2020-06-01","conditions":"Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","enrollment":94},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT01312857","phase":"PHASE2","title":"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-03-07","conditions":"Metastatic Colorectal Cancer","enrollment":75},{"nctId":"NCT07150247","phase":"PHASE2","title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"BRAF V600 Colorectal Cancer","enrollment":20},{"nctId":"NCT01787500","phase":"PHASE1","title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-15","conditions":"BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT01189643","phase":"EARLY_PHASE1","title":"Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)","enrollment":15},{"nctId":"NCT02605265","phase":"PHASE3","title":"Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-10","conditions":"Locally Advanced Rectal Cancer","enrollment":356},{"nctId":"NCT04141995","phase":"PHASE2","title":"FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2021-02-12","conditions":"Pancreas Cancer, Adenocarcinoma of the Pancreas","enrollment":11},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT04239092","phase":"PHASE1","title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","status":"TERMINATED","sponsor":"Actuate Therapeutics Inc.","startDate":"2020-06-05","conditions":"Refractory Cancer, Refractory Neoplasm, Cancer Pediatric","enrollment":40},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT01550510","phase":"PHASE1, PHASE2","title":"Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2011-12","conditions":"Stage IV Colorectal Cancer","enrollment":4},{"nctId":"NCT03328884","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-05-02","conditions":"Breast Cancer Metastatic","enrollment":55},{"nctId":"NCT00576654","phase":"PHASE1","title":"Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma","enrollment":73},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT00200200","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-11-19","conditions":"Hepatic Metastases, Colon Cancer, Rectal Cancer","enrollment":73},{"nctId":"NCT03387592","phase":"PHASE2","title":"CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-03-06","conditions":"Neuroendocrine Carcinoma","enrollment":53},{"nctId":"NCT04514497","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-20","conditions":"Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma","enrollment":28},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT02975882","phase":"PHASE1","title":"Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2017-08-15","conditions":"Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm","enrollment":33},{"nctId":"NCT06760117","phase":"PHASE1","title":"UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Pediatric Solid Tumor","enrollment":39},{"nctId":"NCT06665087","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":110},{"nctId":"NCT06652412","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":124},{"nctId":"NCT04535401","phase":"PHASE1","title":"Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-13","conditions":"Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma","enrollment":10},{"nctId":"NCT01847495","phase":"NA","title":"Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2013-10","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01916447","phase":"PHASE1","title":"A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-09","conditions":"Advanced Gastrointestinal Tumors","enrollment":65},{"nctId":"NCT04366648","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor","status":"COMPLETED","sponsor":"JenKem Technology Co., Ltd.","startDate":"2018-05-04","conditions":"Solid Tumor","enrollment":25},{"nctId":"NCT03970252","phase":"EARLY_PHASE1","title":"Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-24","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT06547203","phase":"PHASE2","title":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-18","conditions":"Colorectal Cancer Metastatic","enrollment":34},{"nctId":"NCT01837862","phase":"PHASE1, PHASE2","title":"A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas","status":"COMPLETED","sponsor":"Julie Krystal","startDate":"2013-10-22","conditions":"Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic","enrollment":36},{"nctId":"NCT03141034","phase":"PHASE2","title":"Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-11-01","conditions":"Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT06321081","phase":"PHASE2","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2024-03-01","conditions":"RAS Mutation, Metastatic Colorectal Cancer, MSS","enrollment":60},{"nctId":"NCT01959139","phase":"PHASE1, PHASE2","title":"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-01-23","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":126},{"nctId":"NCT04074343","phase":"PHASE1","title":"TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2019-08-26","conditions":"Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":20},{"nctId":"NCT05737563","phase":"PHASE3","title":"PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-02-17","conditions":"Esophageal Squamous Cell Carcinoma Abdominal Stage 0","enrollment":380},{"nctId":"NCT03500874","phase":"PHASE3","title":"Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-05-28","conditions":"Colorectal Cancer, Liver Metastases, HAI","enrollment":92},{"nctId":"NCT01897454","phase":"PHASE2","title":"Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-01-27","conditions":"Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer","enrollment":23},{"nctId":"NCT02095132","phase":"PHASE1, PHASE2","title":"Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-28","conditions":"Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT04072445","phase":"PHASE2","title":"Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-10-18","conditions":"Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma","enrollment":28},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT00057837","phase":"PHASE2","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-07-14","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT00033657","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-08-15","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":97},{"nctId":"NCT05160896","phase":"PHASE2","title":"SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-12","conditions":"Advanced Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT05083247","phase":"PHASE2","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Erasme University Hospital","startDate":"2023-03-24","conditions":"Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":256},{"nctId":"NCT02620865","phase":"PHASE1, PHASE2","title":"BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-12","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":2},{"nctId":"NCT03495921","phase":"PHASE3","title":"A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide","status":"TERMINATED","sponsor":"Gradalis, Inc.","startDate":"2018-08-21","conditions":"Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic","enrollment":32},{"nctId":"NCT03726021","phase":"PHASE2","title":"Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2018-01-26","conditions":"Overall Survival","enrollment":47},{"nctId":"NCT03678428","phase":"PHASE3","title":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2021-12-31","conditions":"Metastatic Colorectal Cancer, Liver Metastases","enrollment":92},{"nctId":"NCT03493061","phase":"PHASE2","title":"A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-02-01","conditions":"Colo-rectal Cancer, Liver Metastases","enrollment":60},{"nctId":"NCT04224415","phase":"PHASE2","title":"Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2020-01-31","conditions":"Metastatic Colorectal Cancer","enrollment":35},{"nctId":"NCT04790448","phase":"PHASE1, PHASE2","title":"Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-27","conditions":"Colorectal Cancer Metastatic","enrollment":37},{"nctId":"NCT03251417","phase":"PHASE2","title":"Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Peking University","startDate":"2017-09-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT00354835","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-12-26","conditions":"Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma","enrollment":481},{"nctId":"NCT01528046","phase":"PHASE1","title":"Metformin in Children With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-09-24","conditions":"Solid Tumors, Primary Brain Tumors","enrollment":26},{"nctId":"NCT01926197","phase":"PHASE3","title":"Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-14","conditions":"Pancreatic Cancer","enrollment":27},{"nctId":"NCT01767194","phase":"PHASE2","title":"Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-12","conditions":"Ganglioneuroblastoma, Recurrent Neuroblastoma","enrollment":73},{"nctId":"NCT02562716","phase":"PHASE2","title":"S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2016-01-06","conditions":"Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma","enrollment":147},{"nctId":"NCT02049593","phase":"PHASE1","title":"PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2014-06-12","conditions":"Metastatic Cancer, Unspecified Adult Solid Tumor","enrollment":44},{"nctId":"NCT04247984","phase":"PHASE2","title":"A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-05-01","conditions":"Metastatic Colorectal Cancer","enrollment":264},{"nctId":"NCT05042934","phase":"PHASE1, PHASE2","title":"Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-15","conditions":"Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma","enrollment":""},{"nctId":"NCT01660711","phase":"PHASE2","title":"A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2012-07","conditions":"Pancreatic Adenocarcinoma","enrollment":22},{"nctId":"NCT00381706","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-09-15","conditions":"Esophageal Cancer","enrollment":245},{"nctId":"NCT00655499","phase":"PHASE2","title":"Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-06","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT00025168","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2001-11-01","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT01217437","phase":"PHASE2","title":"Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-22","conditions":"Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma","enrollment":108},{"nctId":"NCT04358354","phase":"PHASE3","title":"Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-10-22","conditions":"Metastatic Gastric Cancer","enrollment":388},{"nctId":"NCT00695201","phase":"PHASE1","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Colon Cancer, Rectal Cancer","enrollment":52},{"nctId":"NCT02368860","phase":"PHASE1","title":"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2013-09-17","conditions":"Pancreatic Cancer","enrollment":33},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03380689","phase":"PHASE1","title":"Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fujian Cancer Hospital","startDate":"2018-01-05","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT00786669","phase":"PHASE1","title":"A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2008-10","conditions":"Solid Tumor","enrollment":13},{"nctId":"NCT00061932","phase":"PHASE2","title":"Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-04","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":115,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Irinotecan"],"phase":"phase_3","status":"active","brandName":"CPT-11 (Irinotecan)","genericName":"CPT-11 (Irinotecan)","companyName":"Epidemiological and Clinical Research Information Network","companyId":"epidemiological-and-clinical-research-information-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CPT-11 (irinotecan) is a topoisomerase I inhibitor that prevents DNA unwinding and repair, leading to DNA damage and cancer cell death. Used for Metastatic colorectal cancer (first-line and second-line), Small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}